Association of Proton Pump Inhibitor and Potassium-Competitive Acid Blocker Use With Discontinuation and Intolerance of Oral 5-Aminosalicylic Acid in Patients With Ulcerative Colitis.

ABSTRACT:

Aims

Proton pump inhibitors (PPIs) and potassium-competitive acid blockers (PCABs) are widely used for acid-related disorders. Recent studies have raised concerns that acid suppression may alter gut microbiota and drug pharmacokinetics, potentially influencing therapeutic outcomes in patients with inflammatory bowel disease. However, the impact of PPI/PCAB use on oral 5-aminosalicylic acid (5-ASA) therapy and intolerance in ulcerative colitis (UC) remains unclear. We aimed to examine whether concomitant PPI/PCAB use was associated with 5-ASA discontinuation and intolerance in patients with UC.

Methods

We retrospectively analyzed consecutive patients who received oral 5-ASA for the first time between 2015 and 2022 at a single tertiary center. Patients receiving concomitant st

SUBMITTER: Otagiri S 

PROVIDER: S-EPMC12860887 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature